{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T21:13:57Z","timestamp":1771017237460,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reumatolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.reuma.2012.02.010","type":"journal-article","created":{"date-parts":[[2013,11,7]],"date-time":"2013-11-07T20:59:19Z","timestamp":1383857959000},"page":"189-194","source":"Crossref","is-referenced-by-count":17,"title":["Terapia biol\u00f3gica: sobrevida y seguridad en padecimientos reum\u00e1ticos. Resultados del Registro Nacional Biobadamex 1.0"],"prefix":"10.1016","volume":"8","author":[{"given":"Lucio","family":"Ventura-R\u00edos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Ba\u00f1uelos-Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda del Carmen","family":"Hern\u00e1ndez-Quiroz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Robles-San Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fedra","family":"Irazoque-Palazuelos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Victoria","family":"Goycochea-Robles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reuma.2012.02.010_bib0005","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/ar2669","article-title":"Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases","volume":"19","author":"Gabriel","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.reuma.2012.02.010_bib0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3899\/jrheum.100951","article-title":"Epidemiology of the Rheumatic Diseases in Mexico. A Study of 5 Regions Based on the COPCORD Methodology","volume":"86","author":"Pel\u00e1ez-Ballestas","year":"2011","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.reuma.2012.02.010_bib0015","first-page":"225","article-title":"A multicenter study to assess the cost of rheumatoid Arthritis (RA), ankylosing spondylitis (AS), and gout","volume":"144","author":"Mould","year":"2008","journal-title":"Gaceta M\u00e9dica de M\u00e9xico"},{"key":"10.1016\/j.reuma.2012.02.010_bib0020","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.23721","article-title":"American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis","volume":"59","author":"Saag","year":"2008","journal-title":"Arthritis and Rheum"},{"key":"10.1016\/j.reuma.2012.02.010_bib0025","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.arcmed.2006.11.008","article-title":"Prescription rheumatology practices among Mexican specialists","volume":"38","author":"Goycochea-Robles","year":"2007","journal-title":"Arch Med Res"},{"key":"10.1016\/j.reuma.2012.02.010_bib0030","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2012.02.010_bib0035","first-page":"10","article-title":"A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults, and an economic evaluation of their cost-effectiveness","author":"Chen","year":"2006","journal-title":"Health Technology Assessment"},{"key":"10.1016\/j.reuma.2012.02.010_bib0040","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.clinthera.2011.05.044","article-title":"Use of biologics in rheumatoid arthritis: current and emerging paradigms of care","volume":"33","author":"Curtis","year":"2011","journal-title":"Clin Ther"},{"key":"10.1016\/j.reuma.2012.02.010_bib0045","first-page":"193","article-title":"Methods to analyse real-world databases and registries Bull of the NYU","volume":"67","author":"Maradit-Kremers","year":"2009","journal-title":"Hosp Joint Dis"},{"key":"10.1016\/j.reuma.2012.02.010_bib0050","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.semarthrit.2010.03.003","article-title":"A comparison of patient characteristics and outcomes in selected European and US rheumatoid arthritis","volume":"40","author":"Curtis","year":"2010","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.reuma.2012.02.010_bib0055","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S1699-258X(08)71810-2","article-title":"Adverse reactions related to the administration of TNF inhibitors. Analysis of a registry of biologic therapy","volume":"4","author":"P\u00e9rez-Zafrilla","year":"2008","journal-title":"Reumatol Clin"},{"issue":"S1","key":"10.1016\/j.reuma.2012.02.010_bib0060","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.reuma.2008.11.007","article-title":"Actualizacion de Biobadaser","volume":"5","author":"Carmona","year":"2009","journal-title":"Reumatol Clin"},{"issue":"Suppl","key":"10.1016\/j.reuma.2012.02.010_bib0065","first-page":"66","article-title":"Registro de acontecimientos adversos con el uso de terapia biol\u00f3gica en enfermedades reum\u00e1ticas en M\u00e9xico: Biobadamex, informe preliminar (C099)","volume":"5","author":"Ventura","year":"2009","journal-title":"Revista Reumatolog\u00eda Cl\u00ednica"},{"key":"10.1016\/j.reuma.2012.02.010_bib0070","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1002\/art.27660","article-title":"No evidence of association between Anti\u2013tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register","volume":"62","author":"Lunt","year":"2010","journal-title":"Arthritis & Rheum"},{"key":"10.1016\/j.reuma.2012.02.010_bib0075","first-page":"8R72","article-title":"Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER","author":"Carmona","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.reuma.2012.02.010_bib0080","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1749-6632.2009.04621.x","article-title":"TNF-Alfa Antagonist survival rate in a cohort of rheumatoid arthritis patients, observed under conditions of standard clinical practice","volume":"1173","author":"Marchesoni","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.reuma.2012.02.010_bib0085","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.medcli.2010.11.032","article-title":"Infections in patients treated with tumor necrosis factor antagonists, incidence, etiology and mortality in the Biobadaser group","volume":"137","author":"P\u00e9rez-Sola","year":"2011","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.reuma.2012.02.010_bib0090","first-page":"CD008794","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","volume":"16","author":"Singh","year":"2011","journal-title":"Chocrane Database Syst Rev"},{"key":"10.1016\/j.reuma.2012.02.010_bib0095","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1590\/S0482-50042011000200005","article-title":"Brazilian Biologic Registry: BiobadaBrasil implentation process and prleiminary results","volume":"51","author":"Titton","year":"2011","journal-title":"Rev Bras Reumatol"},{"key":"10.1016\/j.reuma.2012.02.010_bib0100","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/art.23913","article-title":"Nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis","volume":"59","author":"Lacaille","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2012.02.010_bib0105","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk","volume":"48","author":"Gomez-Reino","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reuma.2012.02.010_bib0110","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.22768","article-title":"Risk of tuberculosis in patients treated with tumor necrosis factor antagonist due to incomplete prevention of reactivation of latent infection","volume":"57","author":"Gomez-Reino","year":"2007","journal-title":"Arthritis and Rheum"},{"key":"10.1016\/j.reuma.2012.02.010_bib0115","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1136\/ard.2006.067660","article-title":"All cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor","volume":"66","author":"Carmona","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reuma.2012.02.010_bib0120","first-page":"7","article-title":"Biologics agents and their use in resource poor countries. Editorial","volume":"32","author":"Adebajo","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reuma.2012.02.010_bib0125","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/art.24511","article-title":"Patient-reported outcomes following biologic therapy in a sample of adults with rheumatoid arthritis recruited from community-based rheumatologists","volume":"61","author":"Katz","year":"2009","journal-title":"Arthritis Rheum"}],"container-title":["Reumatolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X12000940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X12000940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T00:24:52Z","timestamp":1539217492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1699258X12000940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S1699258X12000940"],"URL":"https:\/\/doi.org\/10.1016\/j.reuma.2012.02.010","relation":{},"ISSN":["1699-258X"],"issn-type":[{"value":"1699-258X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}